Blood Transfusion - 4 2017 (July - August)
Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies
Authors:  Pier Mannuccio Mannucci, Massimo Franchini
Pages:  365-368
To cite this article:  Blood Transfus 2017; 15: 365-8
Doi:  10.2450/2016.0030-16
Published online:  25/07/2016

This review focuses on the use of recombinant porcine factor VIII (FVIII) for the treatment of bleeding episodes in patients with severe haemophilia A complicated by inhibitors and in those with acquired haemophilia A due to the onset of anti-FVIII autoantibodies. We present the main characteristics of recombinant porcine factor VIII (FVIII) and provide a summary of the published results of the clinical studies of this novel recombinant FVIII. There is a special emphasis on how the use of recombinant porcine factor VIII (FVIII) is expected to improve the clinical management of these patients. 

Keywords: haemophilia A, inhibitors, bleeding, porcine recombinant FVIII, Obizur.

Full Text Download Back
Share this article: